Observing cannabis use in people with several types of cancer
Follows adults with newly diagnosed cancer who use cannabis or cannabinoids during treatment.
Plain-language title generated from the registry record
Registry title: Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Key facts
- Where
- Manati and San Juan, Puerto RicoSee the 3 sites
Where in Puerto Rico
- Doctors Cancer CenterManati, Puerto RicoTaking people
- Centro Comprensivo de Cancer de UPRSan Juan, Puerto RicoTaking people
- PROncologySan Juan, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06418204
- Record updated
- 4 November 2026
- Original description
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.Read full original descriptionShow less
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Inclusion: Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified); Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment; Participants must be able to comprehend English or Spanish (for survey completion); Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location; Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment; Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey; In the treating provider's opinion, the participant should have a life expectancy of >=6 months. Participants in hospice are not eligible; Optional Sub-study (available at select sites only):; Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU); Must be receiving treatment at the WF CCC and VCU; Must be planning to receive Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.
Exclusion: Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed; Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms; Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy; Participants with a history of HIV, hepatitis B or hepatitis C; Participants with known pregnancy; Participants enrolled in hospice; Optional Substudy (available at select sites only):.